{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:30:48Z","timestamp":1789435848443,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1038\/bjc.2012.153","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T20:04:48Z","timestamp":1336507488000},"page":"1722-1727","source":"Crossref","is-referenced-by-count":215,"title":["Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study"],"prefix":"10.1038","volume":"106","author":[{"given":"D","family":"Strumberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M E","family":"Scheulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Richly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"B\u00fcchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jeffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Boix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Mross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,8]]},"reference":[{"key":"BFbjc2012153_CR1","first-page":"149","volume":"26","author":"H Akbulut","year":"2004","unstructured":"Akbulut H, Icli F, Yalcin B, Demirkazik A, Onur H, Buyukcelik A, Utkan G (2004) Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma. Exp Oncol 26: 149\u2013152","journal-title":"Exp Oncol"},{"key":"BFbjc2012153_CR2","first-page":"3055","volume":"28","author":"R Bitossi","year":"2008","unstructured":"Bitossi R, Sculli CM, Tampellini M, Alabiso I, Brizzi MP, Ferrero A, Ottone A, Bellini E, Gorzegno G, Berruti A, Dogliotti L (2008) Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 28: 3055\u20133060","journal-title":"Anticancer Res"},{"key":"BFbjc2012153_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11912-010-0096-1","volume":"12","author":"A Cercek","year":"2010","unstructured":"Cercek A, Saltz L (2010) Evolving treatment of advanced colorectal cancer. Curr Oncol Rep 12: 153\u2013159","journal-title":"Curr Oncol Rep"},{"key":"BFbjc2012153_CR4","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B (2003) Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 100: 8817\u20138822","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl","key":"BFbjc2012153_CR5","first-page":"141","volume":"47","author":"T Eisen","year":"2011","unstructured":"Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S, Bahl B, Tomczak P, Wagner A, Quinn D (2011) Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell cancer (RCC). Eur J Cancer 47 (Suppl): Abstract 7. 141","journal-title":"Eur J Cancer"},{"key":"BFbjc2012153_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247","journal-title":"Eur J Cancer"},{"key":"BFbjc2012153_CR7","unstructured":"Food and Drug Administration (2001) Guidance for Industry. Bioanalytical Method Validation. Food and Drug Administration: Silver Spring, MD, USA"},{"key":"BFbjc2012153_CR8","first-page":"156","volume-title":"Current Cancer Therapeutics","author":"J Hamilton","year":"1998","unstructured":"Hamilton J, Grem J (1998) Lower gastrointestinal tract cancer. In Current Cancer Therapeutics Kirkwood JM, Lotze MT, Yasko JM (eds) 3rd edn, pp 156\u2013160. Churchill Livingstone, Current Medicine Inc.: Philadelphia, PA, USA"},{"key":"BFbjc2012153_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BFbjc2012153_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2040-2384-1-5","volume":"1","author":"K Mross","year":"2009","unstructured":"Mross K, Fasol U, Frost A, Benkelmann R, Kuhlmann J, B\u00fcchert M, Unger C, Blum H, Hennig J, Milenkova TP, Tessier J, Krebs AD, Ryan AJ, Fischer R (2009) DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 1: 5","journal-title":"J Angiogenes Res"},{"key":"#cr-split#-BFbjc2012153_CR11.1","doi-asserted-by":"crossref","unstructured":"2. Mross K, Frost A, Steinbild S, Hedborn S, B\u00fcchert M, Fasol U, Unger C, Kraetzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res","DOI":"10.1158\/1078-0432.CCR-11-1900"},{"key":"#cr-split#-BFbjc2012153_CR11.2","unstructured":"3. e-pub ahead of print 20 April 2012"},{"key":"BFbjc2012153_CR12","unstructured":"National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network: Fort Washington, PA, USA"},{"key":"BFbjc2012153_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"BFbjc2012153_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/annonc\/mdm399","volume":"19","author":"E Van Cutsem","year":"2008","unstructured":"Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M (2008) An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19: 92\u201398","journal-title":"Ann Oncol"},{"key":"BFbjc2012153_CR15","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658\u20131664","journal-title":"J Clin Oncol"},{"key":"BFbjc2012153_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch\u00fctz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245\u2013255","journal-title":"Int J Cancer"},{"key":"BFbjc2012153_CR17","doi-asserted-by":"crossref","unstructured":"Zopf D, Heinig R, Thierauch K-H, Hirth-Dietrich C, Hafner F-T, Christensen O, Lin T, Wilhelm S, Radtke M (2010) Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites (17\u201321 April) (2010). At the American Association for Cancer Research 101st Annual Meeting, Washington, DC, USA","DOI":"10.1158\/1538-7445.AM10-1666"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2012153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012153","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2012153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:07:14Z","timestamp":1684415234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2012153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["BFbjc2012153"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2012.153","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}